A Monoclonal Antibody against a peptide sequence of Fibrinogen Gamma Chain Acts as an Inhibitor of factor XIII-Mediated Crosslinking of Human Fibrin

Summary

Recurrent hemorrhage has been reported in humans as a result of acquired antibody inhibitors which interfere with the crosslinking of fibrin by factor XIII. One type of these inhibitors (Type III) prevents activated factor XIII from acting on fibrin. We have generated an anti- fibrin monoclonal antibody, called mAb 4A5, which binds to a peptide sequence at the carboxyl-terminus of human fibrinogen γ-chains. MAb 4A5 acts like a Type III inhibitor and prevents proper factor XHI-mediated crosslinking. Pre-incubation of fibrinogen or pooled human plasma with mAb 4A5, but not mAb D2 (specific for the carboxyl terminus of fibrin α-chains), resulted in clots which are soluble in either 5 M urea or 1% monochloroacetic acid. SDS-PAGE and immunoblotting analysis of these clots confirmed that mAb 4A5 inhibited γ-chain crosslinking in plasma clots and fibrin clots. Results from a factor XIII activity assay demonstrated that biotinylcadaverine cross-linking into fibrin by factor XIII could be inhibited by mAb 4A5 but not mAb D2, arguing that mAb 4A5 acted by binding the crosslinking site of factor XIII. Studies of the immunoreactivity of these mAbs with 12 different animal species showed that the γ-chain epitope recognized by mAb 4A5 was more conserved than the α-chain epitope recognized by mAb D2. The species fibrinogens, recognized by mAb 4A5 in binding assays, also showed impaired crosslinking when mAb 4A5 was present during the clotting reaction.

• References

• 1 Aeschlimann D, Paulsson M. Transglutaminases: protein crosslinking enzymes in tissues and body fluids. Thromb Haemost 1994; 71: 402-415
• 2 Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: multifunctional crosslinking enzymes that stabilize tissues. Faseb J 1991; 5: 3071-3077
• 3 Ichinose A, Botlenus RE, Davie EW. Structure of transglutaminases. J Biol Client 1990; 265: 13411-13414
• 4 McDonagh Structure and function of factor XIII. 2nd Ed Haemostasis and Thrombosis. Column RW, Hirsh J, Marder VI, Salzman EW. eds JB Eippincolt Co; Philadelphia, PA: 1987: 289-300
• 5 Nakamura S, Kato A, Sakata V, Aoki N. Bleeding tendency caused by IgG inhibitor to factor XIII treated successfully by cyclophosphamide. Brit J Haematol 1988; 68: 313-319
• 6 Daly HM, Carson PJ, Smith JK. Intracerebral haemorrhage due to acquired factor XIII inhibitor successful response to factor XIII concentrate. Blood Coag Eibrinol 1991; 2: 507-514
• 7 Fukue H, Anderson K, McPhedran P, Clyne L, McDonagh JA. unique factor XIII inhibitor to a fibrin-binding site on factor XIIIa. Blood 1992; 79: 65-74
• 8 Lewis JH, Szeto IL F, Ellis LD, Bayer WL. An acquired inhibitor to coagulation factor XIII. Johns Hopkins Med J 1967; 120: 401-407
• 9 Lorand L, Jacobsen A, Bruner-Lorand J. A pathological inhibitor of fibrin cross-linking. J Clin Invest. 1968; 47: 268-273
• 10 Rosenberg RD, Column RW, Lorand L. A new haemorrhagic disorder with defective fibrin stabilization and cryofibrinogenaemia. Brit. J. Haematol 1974; 26: 269-284
• 11 Lopaeiuk S, Bykowska K, McDonagh JM, McDonagh RP, Yount WJ, Fuller CR, Cooperstcin L, Gray Jr A, Lorand L. Differences between type I autoimmune inhibitors of fibrin stabilization in two patients with severe hemorrhagic disorder. J Clin Invest 1978; 61: 1196-1203
• 12 Matsueda GR, Bernatowicz MS. Characterization of a monoclonal antibody that binds to the carboxyl-terminus of the firbrin gamma-chain. Fibrinogen 3 Proceedings of the International Fibrinogen Workshop. Mosesson MW. et al. (eds). Milwaukee, WI: Elsevier Science Publishers B.V; pp 133-136 1988
• 13 Bernatowicz MS, Matsueda GR. Preparation of peptide-protein immunogens using N-succinimidyl bromoacetate as a heterobifunctional crosslinking reagent. Anal Biochem 1986; 155: 95-102
• 14 Song YC, Sheng D, Taubenfeld SM, Matsueda GR. A microtiter assay for factor XIII using fibrinogen and biotinylcadaverine as substrates. Anal Biochem 1994; 223: 88-92
• 15 Godal HC. An inhibitor to fibrin stabilization factor. Scand J Haemat 1970; 7: 43-48
• 16 Folk JE, Chung SI. Transglutaminases. Methods Enzymol 1985; 113: 358-375
• 17 Song Y, Taubenfeld SM, Sheng D, Matsueda GR. Characterization of a monoclonal antibody directed against the carboxyl-terminus of human factor XIII: an epitope exposed upon denaturation and conserved across species lines. Thromb Haemost 1994; 71: 62-67
• 18 Laudano AP, Doolittle RF. Synthetic peptide derivatives that bind to fibrinogen and prevent the polymerization of fibrin monomers. Proc Natl Acad Sci USA 1978; 75: 3085-3089
• 19 Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME. Measurements of the true affinity constants in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immun Methods 1985; 77: 305-319
• 20 Achyuthan KE, Dobson JV, Greenberg CS. Gly-Pro-Arg-Pro modifies the glutamine residues in the α- and γ-chains of fibrinogen: inhibition of transglutaminase crosslinking. Biochim Biophys Acta 1986; 872: 261-268
• 21 Laudano AP, Doolittle RF. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites, and species differences Biochemistry 1980; 19: 1013-1019
• 22 Blomback B, Procyk R, Adamson L, Hessel B. FXIII induced gelation of human fibrinogen - an alternative thiol enhanced, thrombin independent pathway. Thromb Res 1985; 37: 613-627